TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00866359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast (CC-10004)
Description: Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)
Study: NCT00956111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose
Description: 100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, adjuvanted H1N1 vaccine of 15 μg per dose
Description: 100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
Study: NCT02405273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
Study: NCT04331314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Symbios Bone Graft Material
Description: Patients will receive Symbios Bone Graft Material according to randomization Group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algipore Bone Substitution Material
Description: Patients will receive Algipore Bone Substitution Material according to randomization Group.
Study: NCT02549261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
Study: NCT00956111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose
Description: 100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose
Description: 100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
Study: NCT02549261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.
Study: NCT04422704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based-Intervention
Description: The intervention is intended to address the concerns and needs that emerge from the participants' interviews. The intervention is based on the principles of the process of adaptation to retirement defined by Atchley and the Prochaska and Diclemente Model on the phases of preparation for retirement. The material to be used will be based on existing resources for retired people, awareness through multimedia material and knowledge of possible contributions of different technological devices to the retirement process.~The sessions consisted of showing different exercises and devices to perform physical activities, cognitive training, relaxation activities, counselling about healthy eating and leisure-time activities.
Study: NCT01023724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine 0.45%
Description: Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac 0.09%
Description: Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
Study: NCT02549261

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.
Study: NCT00956111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose
Description: 100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose
Description: 100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
Study: NCT02549261

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
Study: NCT02627586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MICE
Description: MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
Study: NCT00956111

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: 100 adults were assigned to receive 2 doses of placebo 21 days apart.
Study: NCT02126826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: Multiple Rising Doses (oral solution, tablet)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1026706
Description: Multiple Rising Doses (oral solution / tablet, identical to active treatment)
Study: NCT02549261

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
Study: NCT03839446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone + etoposide + gemtuzumab ozogamicin
Description: 10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
Study: NCT03595046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block (20 mL of 0.25% ropivacaine with dexamethasone 5mg)
Description: In group E, The patient was placed in a sitting position and a high-frequency linear ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the thoracic spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle was inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between transverse process and erector spinae muscles, as evidenced by visible linear spread of fluid between erector spinae muscles and the bony acoustic shadows of the transverse process. A total of 20 mL of 0.25% ropivacaine with dexamethasone 5mg was injected here.
Study: NCT02451137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine, 300 U/ml
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT03595046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic paravertebral block(10 mL 0.25% ropivacaine with dexamethasone 5mg)
Description: 2) In group P, an appropriate thoracic spinous precess is located by positioning the probe in the transverse plane. Then the probe is moved laterally to locate the transverse process. The probe is manipulated slightly caudad or cephala to locate the intercostal space. The transverse process is visualized medially with the pleura dipping under the inferolateral aspect. The internal intercostal membrane, which is contiguous with the superior costotransverse ligament, was generally seen as a thin, radiopaque line extending from the transverse process, creating a wedge-shaped pocket, which represents the thoracic paravertebral space. A 22-gauge, facet-tip needle is advanced, in plane, from the lateral aspect of the ultrasound probe. When the needle pierced the internal intercostal membrane, and after aspiration demonstrated the absence of air or blood, 10 mL 0.25% ropivacaine with dexamethasone 5mg deposited in 5-mL increments.
Study: NCT04641104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine 500 MG
Description: A solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% will be administered post-cardiac surgery in patients with lactate levels ≥ 2 mmol / L in the first 6 hours post-ICU admission.
Study: NCT01049815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer hydrochloride
Description: 800-3200 mg with each meal
Study: NCT02451137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine, 100 U/ml
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT01049815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: 600 mg with each meal, up to 1800 mg a day
Study: NCT02451137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background Therapy
Description: Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Therapy
Description: Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
Study: NCT04576702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational aIIV4c
Description: Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV4c
Description: Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: aIIV4
Description: Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
Study: NCT04641104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of NaCl 0.9% will be administered in the placebo group.
Study: NCT00897182

Intervention type: GENETIC
Intervention: microarray analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction
Study: NCT04576702

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RIV4
Description: Licensed, Recombinant Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
Study: NCT01972399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical debridement
Description: This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
Study: NCT02764346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCanCope app
Description: In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iCanCope attention control app
Description: The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality.
Study: NCT03806010

Intervention type: PROCEDURE
Intervention: Quantitative sensory testing
Description: Quantitative sensory testing
Study: NCT00902694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACHIEVE Intervention
Description: Group and individual weight loss counseling and group physical activity classes for 18 months

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: group health classes quarterly with topics not related to weight
Study: NCT01776632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Promotoras led 6 free physical activity (PA) classes per week (2 walking groups, 2 cardio dance, and 2 strength training) at participating churches randomized to the intervention condition. Classes included prayer, warm-up, moderate-to-vigorous PA, cool-down, followed by discussion of a monthly health handout. Participants received copies of the handouts each month by mail, which promoted healthy PA habits. Promotoras conducted up to 5 motivational interviewing calls with each participant over the 2-year intervention using a guide to evaluate participants' PA engagement, barriers to being active, and solutions to those barriers. Promotoras advocated for changes to the social and built environments of the churches and surrounding neighborhoods in order to promote PA and healthy behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer screening
Description: Promotoras provided a 6-session group-based workshop series on cancer screening and prevention (breast, cervical, colorectal, and skin cancers) at participating churches randomized to the attention-control condition. Participants received informational handouts developed by American Cancer Society and the National Cancer Institute to reinforce learning in addition to lists of local cancer screening resources. Promotoras conducted up to 4 motivational interviewing calls with each participant over the 2-year intervention to encourage screening, help overcome barriers to screening, and provide support for goals.
Study: NCT00876902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant P-selectin glycoprotein ligand Ig fusion protein
Description: The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg \[approximately 0.27 mg/kg\] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
Study: NCT04646330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104+anlotinib
Description: Subjects receive AK104 10mg/kg intravenously (IV) every 2-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104+anlotinib
Description: Subjects receive AK104 15mg/kg intravenously (IV) every 3-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104+anlotinib
Description: Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until progression.
Study: NCT03920930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late local infiltration analgesia
Description: Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early local infiltration analgesia
Description: The local infiltration analgesia is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached.
Study: NCT03314311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme
Description: The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
Study: NCT00534976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast sodium
Description: Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Comparator: placebo (unspecified)
Description: Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily
Study: NCT00535119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT04718831

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Spirulina
Description: Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.
Study: NCT03906110

Intervention type: BEHAVIORAL
Intervention: Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials
Description: Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.

Intervention type: BEHAVIORAL
Intervention: Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials
Description: Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.